|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Echilibru hormonal pentru barbati si femei: Diindolylmethane si Indole-3-Carbinol
39 40
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Serenoa Repens un fito farmaceutic indicat la hiperplazia benigna de prostata, studiu randomizat, dublu-orb, placebo controlat.
Palmier
pitic - Serenoa Repens, Saw Palmetto (Sabal Serulata) foto
pentru
Serenoa, 
pentru
Urzica, in mai mult de 80% cazuri, spune departamentul
farmacologic
| Urzica (Urtica Dioica) din: Farmacia Naturala |
 |
- Urzica contine: Vitaminele C, B2, K, acid pantotenic, acid folic, enzime, minerale, acid linolenic, acid linoleic, acid palmitic, acid succinic, acetilcholina, clorofila, xantofila, violaxantina, acid formic, ulei volatil, qercitina, flavonoizi, steroli, sitosteroli, stigmasterol, camferol, coproporfirina, 5-hidroxitriptamina, glucochinona, secoisolariciresinol, lignani, lectina, aglutinina (Urtica Dioica Aglutinina) (UDA), care are efect antiviral si imunomodulator.
- Urzica are actiune diuretica,
- Urzica imbunatateste lactatia,
- Urzica reduce eczemele la copii,
- Urzica indicat in tratamentul de acnee.
- Urzica decongestioneaza mucoasa nazala, imbunatatind respiratia.
- Urzica are actiune favorabila in timpul menstruatiei,
60
Urzica (Urticae radix) radacina un
inhibitor de aromataza
61 Urzica (Urticae radix) radacina cu
efect de inhibare la hiperplazia benigna de prostata
62 Urzica (Urticae
radix) radacina cu
continutul de lignani interfera cu 5 alfa difidrotestosteron care se
leaga de SHBG
| Bibliografie-Referinte: |
 |
| Informatii din bibliografia electronica la tema: Nutritie si sanatate |
1
Gerber GS. Phytotherapy
for benign prostatic hyperplasia. Section of Urology, University of Chicago,
5841 S. Maryland Avenue, MC 6038, Chicago, IL 60637, USA. Curr Urol Rep.
2002 Aug;3(4):285-91.
- Willetts KE, Clements MS, Champion S, Ehsman
S, Eden JA. Serenoa
repens extract for benign prostate hyperplasia: a randomized controlled trial. Natural
Therapies Unit, Royal Hospital for Women, Randwick, Australia. BJU Int. 2003
Aug;92(3):267-70.
2 Boyle P, Robertson C, Lowe F, Roehrborn
C. Updated
meta-analysis of clinical trials of Serenoa repens extract in the treatment of
symptomatic benign prostatic hyperplasia. Department of Epidemiology and
Biostatistics, European Institute of Oncology, via Ripamonti 435, 20141 Milan,
Italy. BJU Int. 2004 Apr;93(6):751-6.
3 Champault G, Patel JC, Bonnard AM. A
double-blind trial of an extract of the plant Serenoa repens in benign prostatic
hyperplasia. Br J Clin Pharmacol. 1984 Sep;18(3):461-2
4 FEURT SD, FOX LE. A
note on the effects of feeding saw palmetto berries, Serenoa repens (Bartram)
Small, to rats. J Am Pharm Assoc Am Pharm Assoc (Baltim). 1954
Oct;43(10):636-8.
5 Wilt TJ, Ishani A, Rutks
I, MacDonald R. Phytotherapy
for benign prostatic hyperplasia.Minneapolis VA Center for Chronic Diseases
Outcomes Research, MN 55417, USA. Public Health Nutr. 2000 Dec;3(4A):459-72.
6 Fong YK, Milani S, Djavan B. Role
of phytotherapy in men with lower urinary tract
symptoms. Department of Urology, University of Vienna, Vienna, Austria. Curr
Opin Urol. 2005 Jan;15(1):45-8.
7 Dreikorn K, Berges R, Pientka L,
Jonas
U. Phytotherapy
of benign prostatic hyperplasia. Current evidence-based evaluation Urologische
Klinik, Zentralkrankenhaus, St.-Jürgen-Str., 28205 Bremen. Urologe A. 2002
Sep;41(5):447-51
8. Lowe FC, Dreikorn K, Borkowski A,
Braeckman
J, Denis L, Ferrari P, Gerber
G,
Levin R, Perrin P, Senge T. Review
of recent placebo-controlled trials utilizing phytotherapeutic agents for treatment
of BPH. Department of Urology, St. Luke's-Roosevelt Hospital, New York, New
York 10019, USA. Prostate. 1998 Nov 1;37(3):187-93
9 Kondás J, Philipp V, Diószeghy
G. Sabal
serrulata extract in the management of symptoms of prostatic hypertrophy Fóvárosi
Onkormányzat Péterfy Sándor utcai Kórház-Rendelóintézet,
Urológiai-sebészeti Osztály, Budapest. Orv Hetil. 1997
Feb 16;138(7):419-21
10 Vahlensieck
W Jr, Völp A,
Lubos W, Kuntze M. Benign
prostatic hyperplasia--treatment with sabal fruit extract. A treatment study
of 1,334 patients Urologische Klinik und Poliklinik, Klinikum Grosshadern
der Universität München. Fortschr Med. 1993 Jun 30;111(18):323-6.
11 Tasca A, Barulli M, Cavazzana A,
Zattoni F, Artibani W, Pagano F. Treatment
of obstructive symptomatology caused by prostatic adenoma with an extract of
Serenoa repens. Double-blind clinical study vs. placebo Minerva Urol Nefrol.
1985 Jan-Mar;37(1):87-91.
12 Aliaev IuG, Vinarov AZ, Lokshin
KL, Spivak LG. Extracts
Serenoa repens in the treatment of prostatic adenoma and chronic abacterial
prostatitis: results of short-term (3-month courses) therapy Urologiia.
2007 Mar-Apr;(2):80-2.
13 Wilt T, Ishani A, Stark G, MacDonald
R, Mulrow C, Lau J. Serenoa
repens for benign
prostatic hyperplasia. General Internal Medicine (111-0), Minneapolis VA/VISN
13 Center for Chronic Diseases Outcomes Research, One Veterans Drive, Minneapolis,
Minnesota 55417,
USA. Cochrane Database Syst Rev. 2000;(2):CD001423.
- Wilt T, Ishani A, Mac Donald
R. Serenoa
repens for benign prostatic hyperplasia. General Internal Medicine (111-0),
Minneapolis VA/VISN 13 Center for Chronic Disease Outcomes Research, One Veterans
Drive, Minneapolis, Minnesota 55417,
USA. Cochrane Database Syst Rev. 2002;(3):CD001423.
- Gordon AE, Shaughnessy AF. Saw
palmetto for prostate disorders. Harrisburg Family Practice Residency Harrisburg,
Pennsylvania 17110-2098, USA. agordon@pinnacle.health.org Am Fam Physician. 2003
Mar 15;67(6):1281-3.
- Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C. Saw
palmetto extracts for treatment of benign prostatic hyperplasia: a systematic
review. Department of Veterans Affairs Coordinating Center of the Cochrane
Collaborative Review Group in Prostatic Diseases and Urologic Malignancies, Minneapolis
Veterans Affairs Medical Center, Minn 55417, USA. JAMA. 1998 Nov 11;280(18):1604-9.
- McPartland JM, Pruitt PL. Benign
prostatic hyperplasia treated with saw palmetto: a literature search and an experimental
case study. Department of Family Practice, University of Vermont, USA. J
Am Osteopath Assoc. 2000 Feb;100(2):89-96.
- Marks LS, Partin AW, Epstein JI, Tyler VE, Simon I, Macairan ML, Chan TL, Dorey
FJ, Garris JB, Veltri RW, Santos PB, Stonebrook KA, deKernion JB. Effects
of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia.Department
of Urology, University of California Los Angeles School of Medicine, Los Angeles,
CA, USA. J Urol. 2000 May;163(5):1451-6.
- Preuss HG, Marcusen C, Regan J, Klimberg IW, Welebir TA, Jones WA. Randomized
trial of a combination of natural products (cernitin, saw palmetto, B-sitosterol,
vitamin E) on symptoms of benign prostatic hyperplasia (BPH). Department
of Physiology and Biophysics, Georgetown University Medical Center, Washington,
DC 20007, USA.Int Urol Nephrol. 2001;33(2):217-25.
14 Weisser H, Tunn S, Behnke B, Krieg
M. Effects
of the sabal serrulata extract IDS 89 and its subfractions on 5 alpha-reductase
activity in human benign prostatic hyperplasia. Institute of Clinical Chemistry,
Transfusion and Laboratory Medicine, University Clinic Bergmannsheil, Bochum,
Federal Republic of Germany. Prostate. 1996 May;28(5):300-6.Links
15 Wagner
H, Flachsbarth H, Vogel G. A
New Antiphlogistic Principle from Sabal serrulata, II. Institut für
pharmazeutische Arzneimittellehre der Universität München. Planta
Med. 1981 Mar;41(3):252-8.
16 Di
Silverio F, D'Eramo G, Lubrano C, Flammia GP, Sciarra A, Palma E, Caponera
M, Sciarra F. Evidence
that Serenoa repens extract displays an antiestrogenic activity in prostatic
tissue of benign prostatic hypertrophy patients.Department of Urology U.
Bracci, University of Rome La Sapienza, Italy. Eur Urol. 1992;21(4):309-14.
17 Sultan
C, Terraza A, Devillier C, Carilla E, Briley M, Loire C, Descomps B. Inhibition
of androgen metabolism and binding by a liposterolic extract of "Serenoa
repens B" in human foreskin fibroblasts. J Steroid Biochem. 1984 Jan;20(1):515-9.
18 Giannakopoulos X, Baltogiannis
D, Giannakis D, Tasos A, Sofikitis N, Charalabopoulos K, Evangelou A. The
lipidosterolic extract of Serenoa repens in the treatment of benign prostatic
hyperplasia: a comparison of two dosage regimens. Department of Urology,
Ioannina University School of Medicine, Ioannina, Greece. Adv Ther. 2002 Nov-Dec;19(6):285-96.
19 Gerber GS, Zagaja GP, Bales
GT, Chodak GW, Contreras BA. Saw
palmetto (Serenoa repens) in men with lower urinary tract symptoms: effects
on
urodynamic parameters
and voiding symptoms. Department of Surgery, University of Chicago Pritzker
School
of Medicine, Illinois, USA. Urology. 1998 Jun;51(6):1003-7.
20 Gerber GS. Saw
palmetto for the treatment of men with lower urinary tract symptoms.
Section of Urology, Department of Surgery, University of Chicago Pritzker
School of Medicine, Chicago, Illinois, USA. J Urol. 2000 May;163(5):1408-12
21 Gerber GS, Kuznetsov D, Johnson
BC, Burstein JD. Randomized,
double-blind, placebo-controlled trial of saw palmetto in men with lower urinary
tract symptoms. Section of Urology, Department of Surgery, University of
Chicago Pritzker School of Medicine, Chicago, Illinois, USA Urology. 2001 Dec;58(6):960-4;
discussion 964-5.
22 Tasca A, Barulli M, Cavazzana
A, Zattoni F, Artibani W, Pagano F. Treatment
of obstructive symptomatology caused by prostatic adenoma with an extract of
Serenoa repens. Double-blind clinical study vs. placebo Minerva Urol Nefrol.
1985 Jan-Mar;37(1):87-91.
23 Gerber GS, Fitzpatrick JM. The
role of a lipido-sterolic extract of Serenoa repens in the management of lower
urinary tract symptoms associated with benign prostatic hyperplasia. Division
of Urology, University of Chicago Medical School, Chicago, IL 60637, USA. BJU
Int. 2004 Aug;94(3):338-44.
24 Koch E. Extracts
from fruits of saw palmetto (Sabal serrulata) and roots of stinging nettle
(Urtica dioica): viable alternatives in the medical treatment of benign prostatic
hyperplasia
and associated lower urinary tracts symptoms. Department of Pharmacology,
Dr. Willmar Schwabe Arzneimittel GmbH, Karlsruhe, Germany. Planta
Med. 2001 Aug;67(6):489-500.
25. Kaufman, K. D. Androgens and
alopecia. Mol. Cell Endocrinol. 2002; 198(1-2): 89-95
- Chizick, S., et al. Natural preparation for treatment of male pattern
hair
loss. U.S. Patent #5,972,345. 1999.
26. Krieg M, Nass R, Tunn S. Effect of aging
on endogenous level of 5 alpha-dihydrotestosterone, testosterone, estradiol,
and estrone in epithelium and stroma of normal and
hyperplastic human prostate. Institute of Clinical Chemistry and Laboratory
Medicine, University Clinic Bergmannsheil, Bochum, Germany. J Clin Endocrinol
Metab. 1993 Aug;77(2):375-81.
27. Dvorkin L, Song KY. Herbs for benign prostatic hyperplasia. Center for Integrative
Therapies in Pharmaceutical Care, Massachusetts College of Pharmacy and Health
Sciences, Boston, MA 02115-5896, USA. Ann Pharmacother. 2002 Sep;36(9):1443-52.
28. Farnsworth WE, Roles of estrogen and SHBG in prostate physiology. The Prostate
1996; 28:17-23.
29. Nakhla AM, Romas NA, Rosner W. Estradiol activates the prostate androgen
receptor and prostate-specific antigen secretion through the intermediacy of
sex hormone-binding globulin. Department of Medicine, St. Luke's/Roosevelt Hospital
Center, New York, New York 10019 and the College of Physicians and Surgeons,
Columbia University, New
York, New York 10019, USA.
J Biol Chem. 1997 Mar 14;272(11):6838-41.
30 Dean
K. Saw palmetto (Serenoa repens), and nettles, for male pattern baldness. HerbalGram.
2000;49:31.
31 Sökeland
J, Albrecht J. Combination of Sabal and Urtica extract vs. finasteride in benign
prostatic hyperplasia (Aiken stages I to II. Comparison of therapeutic effectiveness
in a one year double-blind study Urologische Klinik Dortmund, Lehrkrankenhaus
der Universitat Münster. Urologe A. 1997 Jul;36(4):327-33.
- Sökeland J. Combined sabal and urtica extract compared with
finasteride in men with benign prostatic hyperplasia: analysis of prostate volume
and therapeutic outcome. Urological Clinic of Dortmund, Training Hospital of
the University
of
Münster,
Germany. BJU Int. 2000 Sep;86(4):439-42.
- Gordon AE, Shaughnessy AF. Saw palmetto for prostate disorders. Harrisburg
Family Practice Residency Harrisburg, Pennsylvania 17110-2098, USA. agordon@pinnacle.health.org
Am Fam Physician. 2003
Mar 15;67(6):1281-3.
32 Plosker
GL, Brogden RN. Serenoa repens (Permixon). A review of its pharmacology and therapeutic
efficacy in benign prostatic hyperplasia. Adis International Limited, Auckland,
New Zealand. Drugs Aging. 1996 Nov;9(5):379-95.
33. Frydoonfar HR, McGrath DR, Spigelman AD. The effect of indole-3-carbinol
and sulforaphane on a prostate cancer cell line. Discipline of Surgical Science,
Faculty of Health, The University of Newcastle, New South Wales, Australia. ANZ
J Surg. 2003 Mar;73(3):154-6.
34. Zeligs MA, Sepkovic DW, Manrique CA, Macksalka M, Williams DE, Bradlow
HL, "Absorption-enhanced
3,3-Diindolylmethane: human use in HPV-related, benign and pre-cancerous conditions." American Association of Cancer Research, (42) 2002, #103483.
35. Brind J, Strain G, Miller L, Zumoff B, Vogelman J, Orentreich N. Obese men
have elevated plasma levels of estrone sulfate. Orentreich Foundation for the
Advancement of Science Inc., Biomedical Research Station, Cold Spring-on-Hudson,
NY 10516. Int J Obes. 1990 Jun;14(6):483-6.
36. Klaiber EL, Broverman DM, Haffajee CI, Hochman JS, Sacks GM, Dalen JE. Serum
estrogen levels in men with acute myocardial infarction. Am J Med. 1982 Dec;73(6):872-81.
37. Phillips GB, Castelli WP, Abbott RD, McNamara PM. Association of hyperestrogenemia
and coronary heart disease in men in the Framingham cohort. Am J Med. 1983 May;74(5):863-9.
38. Philips GB, Evidence for hyperoestrogenaemia as a risk factor for myocardial
infarction in men. Lancet 1976; 2(7975): 14-18.
39
Edgar AD, Levin R, Constantinou
CE, Denis L. A critical review of the pharmacology of the plant extract of
Pygeum africanum in the treatment of LUTS. Fournier
Pharma, Daix, France. Neurourol Urodyn. 2007;26(4):458-63; discussion 464.
40 Lowe FC, Dreikorn K, Borkowski A, Braeckman J, Denis L, Ferrari P, Gerber
G, Levin R, Perrin P, Senge T. Review of recent placebo-controlled trials utilizing
phytotherapeutic agents for treatment of BPH. Department of Urology, St. Luke's-Roosevelt
Hospital, New York, New York 10019, USA. Prostate. 1998 Nov 1;37(3):187-93
41 Barlet A, Albrecht J, Aubert A, Fischer M, Grof F, Grothuesmann HG, Masson
JC, Mazeman E, Mermon R, Reichelt H, et al. Efficacy of Pygeum africanum extract
in the medical therapy of urination disorders due to benign prostatic hyperplasia:
evaluation of objective and subjective parameters. A placebo-controlled double-blind
multicenter study Laboratoires Debat, Paris, Frankreich. Wien Klin Wochenschr.
1990 Nov 23;102(22):667-73.
42 Levin RM, Levin SS, Zhao Y, Buttyan R. Cellular and molecular aspects of
bladder hypertrophy.Albany College of Pharmacy, N.Y., USA. Eur Urol. 1997;32
Suppl
1:15-21.
43. Levin RM, Whitbeck C, Horan P, Bellamy F. Low-dose tadenan protects the rabbit
bladder from bilateral ischemia/reperfusion-induced contractile dysfunction.
Phytomedicine. 2005 Jan;12(1-2):17-24.
44 Chatelain C, Autet W, Brackman F. Comparison of once and twice daily dosage
forms of Pygeum africanum extract in patients with benign prostatic hyperplasia:
a randomized, double-blind study, with long-term open label extension. Department
of Urology, Pitié-Salpétrière
Hospital, Paris, France. Urology. 1999 Sep;54(3):473-8.
45 Andro M-C, Riffaud J-P. Pygeum africanum extract for the treatment of patients
with benign prostatic hyperplasia: A review of 25 years of published experience.
Curr Ther Res 1995;56:796
46 Krzeski T, Kazón M, Borkowski A, Witeska
A, Kuczera J. Combined extracts of Urtica dioica and Pygeum africanum in the
treatment of benign prostatic hyperplasia: double-blind comparison of two doses.
Warsaw School of Medicine, Poland.
Clin
Ther. 1993 Nov-Dec;15(6):1011-20.
47 Edgar AD, Levin R, Constantinou CE, Denis L. A critical review of the pharmacology
of the plant extract of Pygeum africanum in the treatment of LUTS. Fournier Pharma,
Daix, France. Neurourol Urodyn.
2007;26(4):458-63;
discussion 464.
48 Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the role of
5 alpha-reductase inhibitors in benign prostatic hyperplasia Urol. Universitätsklinik,
Frauen- und Kopfklinik, Anichstrasse 35, 6020 Innsbruck/Osterreich. Urologe A.
2002 Sep;41(5):412-24.
49 Iehlé C, Délos S, Guirou O, Tate
R, Raynaud JP, Martin PM. Human prostatic steroid 5 alpha-reductase isoforms--a
comparative study of selective inhibitors. Laboratoire de Cancérologie Expérimentale, Faculté de
Médecine, Marseille, France. J Steroid Biochem Mol Biol. 1995 Sep;54(5-6):273-9.
50 Wilt T, Ishani A, Mac Donald R, Rutks I, Stark G. Pygeum africanum for benign
prostatic hyperplasia. General Internal Medicine (111-0), Minneapolis VA/VISN
13 Center for Chronic Disease Outcomes Research, One Veterans Drive, Minneapolis,
Minnesota 55417, USA. Cochrane Database Syst Rev. 2002;(1):CD001044.
51 Bassi P, Artibani W, De Luca V, Zattoni F, Lembo A. Standardized extract
of Pygeum africanum in the treatment of benign prostatic hypertrophy. Controlled
clinical study versus placebo Minerva Urol Nefrol. 1987 Jan-Mar;39(1):45-50.
52 Chatelain C, Autet W, Brackman F. Comparison of once and twice daily dosage
forms of Pygeum africanum extract in patients with benign prostatic hyperplasia:
a randomized, double-blind study, with long-term open label extension. Department
of Urology, Pitié-Salpétrière
Hospital, Paris, France. Urology. 1999 Sep;54(3):473-8.
53 Breza J, Dzurny O, Borowka A, Hanus T, Petrik R, Blane G, Chadha-Boreham
H. Efficacy and acceptability of tadenan (Pygeum africanum extract) in the treatment
of benign prostatic hyperplasia (BPH): a multicentre trial in central Europe.
Department of Urology, University Hospital, Bratislava, Slovak Republic. Curr
Med Res Opin. 1998;14(3):127-39.
54 Levin RM, Das AK, Haugaard N, et al. Beneficial effects of Tadenan therapy
after two weeks of partial obstruction in the rabbit. Neurourol Urodyn. 1997;16(6):583-99
55 Yablonsky F, Nicolas V, Riffaud JP, Bellamy F. Antiproliferative effect of
Pygeum africanum extract on rat prostatic fibroblasts. Laboratoires Debat, groupe
Fournier, Garches, France. J Urol. 1997 Jun;157(6):2381-7.
56 Isaacs JT. Importance of the natural history of benign prostatic hyperplasia
in the evaluation of pharmacologic intervention. Prostate Suppl. 1990;31-7.
57 Levin RM, Das AK. A scientific basis for the therapeutic effects of Pygeum
africanum and Serenoa repens. Division of Basic and Pharmaceutical Sciences,
Albany College of Pharmacy, NY 12208, USA. Urol Res. 2000 Jun;28(3):201-9.
58 Safarinejad MR. Urtica dioica for treatment of benign prostatic hyperplasia:
a prospective,
randomized, double-blind, placebo-controlled, crossover study. Department
of Urology, Urology Nephrology Research Center, Shaheed Beheshti University
of Medical Sciences,
Tehran, Iran. J Herb Pharmacother. 2005;5(4):1-11.
59 Wilt TJ, Ishani A, Rutks
I, MacDonald R. Phytotherapy
for benign prostatic hyperplasia.Minneapolis VA Center for Chronic
Diseases Outcomes Research, MN 55417, USA. Public Health Nutr. 2000
Dec;3(4A):459-72.
60 Ganser D, Spiteller G. Aromatase
inhibitors from Urtica dioica roots. Planta
Medica. 1995;61:138-140
61 Lichius JJ, Muth C. The
inhibiting effects of Urtica dioica root extracts on experimentally induced
prostatic
hyperplasia in the mouse. Institut für
Pharmazeutische Biologie, Philipps-Universität,
Marburg, Germany. Planta Med. 1997 Aug;63(4):307-10.
62 Schöttner M, Spiteller G, Gansser
D. Lignans
interfering with 5 alpha-dihydrotestosterone binding to human sex hormone-binding
globulin. Lehrstuhl für organische
Chemie, Universität
Bayreuth, Germany. J Nat Prod. 1998 Jan;61(1):119-21.
Parerea din pasajele acestui site nu a fost independent cercetate sau confirmate.
|
Anti-Aging-Systeme
© 2008
|
Design by NB |